AI & ChatGPT searches , social queriess for OFATUMUMAB
Search references for OFATUMUMAB. Phrases containing OFATUMUMAB
See searches and references containing OFATUMUMAB!
Search references for OFATUMUMAB. Phrases containing OFATUMUMAB
See searches and references containing OFATUMUMAB!OFATUMUMAB
Medication
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved
Ofatumumab
Artificial stimulation of the immune system to treat cancer
CD20 protein, ofatumumab binds to a separate, small loop. This may explain their different characteristics. Compared to rituximab, ofatumumab induces complement-dependent
Cancer_immunotherapy
Disease that damages the myelin sheaths around nerves
22-0.25 Zeposia Ozanimod [better source needed] Oral 0.18-0.24 Kesimpta Ofatumumab Subcutaneous 70% 0.09-0.14 Mavenclad Cladribine Oral 70% 0.1-0.14 Lemtrada
Multiple_sclerosis
Danish healthcare company
crisis, GlaxoSmithKline exited oncology, which impacted co-development of ofatumumab, an oncology-directed product. In tandem with the sale of the plant, the
Genmab
Biopharmaceutical drug
developed: ocrelizumab, humanized (90%-95% human) B cell-depleting agent. ofatumumab (HuMax-CD20) a fully human B cell-depleting agent. Third-generation anti-CD20s
Rituximab
American musician and television host
function, and monthly injections of B cell suppressants ocrelizumab and ofatumumab have largely prevented long-term progression that largely ended the performing
David_Osmond
Mammalian protein found in humans
CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active
CD20
Chronic blistering skin disease
this disease, other anti-CD20 drugs such as ocrelizumab, veltuzumab, and ofatumumab have been explored as potential treatments. Key companies in Pemphigus
Pemphigus_vulgaris
Bone marrow cancer in which lymphocytes are overproduced
antibodies that have been used for the treatment of CLL include: Rituximab Ofatumumab Obinutuzumab These agents are usually used in refractory/relapsed disease
Chronic_lymphocytic_leukemia
Medication
Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid:
Elranatamab
Medical drug glass
completed pivotal phase III trial DUO comparing duvelisib monotherapy with ofatumumab led to its approval for CLL/SLL An extension trial to DUO was completed
Phosphoinositide 3-kinase inhibitor
Phosphoinositide_3-kinase_inhibitor
Swiss multinational pharmaceutical corporation
company acquired the remaining rights to the CD20 monoclonal antibody Ofatumumab from GlaxoSmithKline for up to $1 billion. In October the company acquired
Novartis
Antibodies from clones of the same blood cell
Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Rituximab Trastuzumab Monoclonal antibodies
Monoclonal_antibody
Index of articles associated with the same name
in trade names. Examples include: HuMax-CD4 (zanolimumab) HuMax-CD20 (ofatumumab) HuMax-EGFr (zalutumumab) This set index article includes a list of related
HuMax
Medication used in cancer treatment
ibrutinib down-modulates the expression of CD20 (target of rituximab/ofatumumab) by targeting the CXCR4/SDF1 axis. Together, these data are consistent
Ibrutinib
Monoclonal antibody
Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid:
Mosunetuzumab
July 2020. Retrieved 23 January 2020. "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients
List of therapeutic monoclonal antibodies
List_of_therapeutic_monoclonal_antibodies
Chemical compound
Multiple myeloma Advanced melanoma Phase III A comparison of dinaciclib and ofatumumab for treatment of CLL Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar
Dinaciclib
Pharmaceutical drug classification
Repotrectinib L01EX29 Vimseltinib QL01EX90 Toceranib L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab
ATC_code_L01
Type of cytotoxic lymphocyte
killing mechanism of some monoclonal antibodies like rituximab (Rituxan), ofatumumab (Azzera), and others. The contribution of antibody-dependent cell-mediated
Natural_killer_cell
abnormal temperature increases, headache, abdominal pain, and vomiting. Ofatumumab IV Anti-CD20 antibody. Chronic lymphocytic leukaemia Neutropenia, pneumonia
List_of_antineoplastic_agents
Pharmaceutical drug
monoclonal antibody, has been approved for some indications. Ocrelizumab, ofatumumab, and "third-generation" anti-CD20 monoclonals are in development.[citation
Belimumab
Ocusulf Oczyesa odanacatib (USAN) odronextamab (INN) odulimomab (INN) ofatumumab (INN) ofloxacin Ogestrel Ogivri oglufanide disodium (USAN) Ogsiveo Ohtuvayre
List_of_drugs:_O–Op
Pharmaceutical compound
Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab† Panitumumab Patritumab§ Pritumumab§ Radretumab§ Ramucirumab
Indium (111In) altumomab pentetate
Indium_(111In)_altumomab_pentetate
Overview article
Ocrelizumab (Ocrevus) which is also approved for primary progressive (PPMS) Ofatumumab (Kesimpta) is another anti-CD20 monoclonal antibody. Ublituximab (Briumvi)
Multiple sclerosis drug pipeline
Multiple_sclerosis_drug_pipeline
Form of immunotherapy
Genentech 3/28/2017 intravenous humanized CD20 Multiple sclerosis 761053 Link ofatumumab Arzerra Glaxo Grp 10/26/2009 intravenous fully human CD20 Chronic lymphocytic
Monoclonal_antibody_therapy
American physician (born 1949)
2017;376(3):221–234. doi:10.1056/NEJMoa1601277 Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–557
Stephen_L._Hauser
Indication Ivacaftor Vertex Pharmaceuticals cystic fibrosis with CFTR mutation Ofatumumab Novartis Pharmaceuticals chronic lymphocytic leukemia Ceritinib Novartis
List of drugs granted breakthrough therapy designation
List_of_drugs_granted_breakthrough_therapy_designation
Medical condition
PCDLBCL, NOS and ultimately may prove useful in PCDLBCL, LT. These include: ofatumumab, a monoclonal antibody that is stronger than rituximab in binding to CD20;
Primary cutaneous diffuse large B-cell lymphoma, leg type
Primary_cutaneous_diffuse_large_B-cell_lymphoma,_leg_type
Colombian-American neuroscientist and entrepreneur
in the clinic including Aimovig (erenumab) for migraine and Kesimpta (ofatumumab) for multiple sclerosis.[citation needed] Dolmetsch was also involved
Ricardo_Dolmetsch
Approaches to managing the disease
beta-1b; monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab; and immunomodulators: glatiramer acetate, mitoxantrone
Management of multiple sclerosis
Management_of_multiple_sclerosis
PI3K inhibitor
increased risk of death with duvelisib compared to the monoclonal antibody ofatumumab. The rate of serious side effects, dose modifications, and deaths resulting
Duvelisib
Medical condition
anti-CD20 monoclonal antibodies such as ocrelizumab, veltuzumab, and ofatumumab have been suggested for the management of pemphigus. Immunoadsorption
Pemphigus_erythematosus
those diseases, as antibodies against CD20 exist: e.g. Rituximab and Ofatumumab, with several more in development. Similarly, anti-CD20 monoclonal antibody
List of human clusters of differentiation
List_of_human_clusters_of_differentiation
Monoclonal antibody
Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab† Panitumumab Patritumab§ Pritumumab§ Radretumab§ Ramucirumab
Minretumomab
Pharmaceutical drug classification
Ocrelizumab L04AG09 Emapalumab L04AG10 Inebilizumab L04AG11 Anifrolumab L04AG12 Ofatumumab L04AG13 Teprotumumab L04AG14 Ublituximab L04AG15 Divozilimab L04AG17 Seniprutug
ATC_code_L04
Pharmaceutical compound
Narnatumab§ Necitumumab Nesvacumab§ Nivolumab# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab† Panitumumab Patritumab§ Pritumumab§ Radretumab§ Ramucirumab
Naptumomab_estafenatox
Overview of and topical guide to immunology
Fontolizumab Inebilizumab Ixekizumab Maslimomab Morolimumab Nipocalimab Ofatumumab Olokizumab Pexelizumab Reslizumab Risankizumab Rovelizumab Rozanolixizumab
Outline_of_immunology
daclizumab and CD20 monoclonal antibodies such as rituximab, ocrelizumab and ofatumumab have all shown some benefit and are under study as potential treatments
Research in multiple sclerosis
Research_in_multiple_sclerosis
Medical condition
Ketterl TG, Messinger YH, Niess DR, Gilles E, Engel WK, Perkins JL (2013). "Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma"
Anti-Hu associated encephalitis
Anti-Hu_associated_encephalitis
OFATUMUMAB
OFATUMUMAB
OFATUMUMAB
OFATUMUMAB
Boy/Male
Hindu
Boy/Male
Tamil
Yuhandhar | யà¯à®¹à®¾à®¨à¯à®¤à®¾à®°Â
Yes
Boy/Male
Tamil
Digamber | திகமà¯à®ªà®°
Naked, Unencumbered
Girl/Female
Arabic, Muslim
Nectar
Boy/Male
Cambodian Hindi Indian
Sun.
Girl/Female
American, British, Celtic, English, French, Gaelic
Pledge; Oath; Man
Boy/Male
Teutonic German
Strong fighter.
Girl/Female
Welsh
Offspring.
Girl/Female
Indian
Butterfly
Girl/Female
Tamil
Gold, Snow
OFATUMUMAB
OFATUMUMAB
OFATUMUMAB
OFATUMUMAB
OFATUMUMAB